Pexelizumab

Summary

Pexelizumab (CHEMBL2107979) is a phase-3 clinical-stage antibody; indicated across 2 conditions including coronary artery disorder and acute myocardial infarction.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 2 conditions
• Clinical trials: 2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2107979
Name	Pexelizumab
Type	Antibody
Max phase	3

Also known as: H-5G1.1 SCFV, H5G1.1 SCFV, H5G1.1 SCFV (CDR), Pexelizumab, PEXELIZUMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
coronary artery disorder	3	MONDO:0005010	EFO:0001645
acute myocardial infarction	3	MONDO:0004781	EFO:0008583

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00048308	PHASE3	COMPLETED	Effect of Pexelizumab on All-Cause Mortality and Myocardial Infarction in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardio-Pulmonary Bypass
NCT00091637	PHASE3	COMPLETED	Pexelizumab in Conjunction With Angioplasty in Acute Myocardial Infarction (APEX-AMI)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).